Factor

EQS-News: Biotest AG increased sales by 32% in the financial year 2023

Retrieved on: 
Wednesday, April 10, 2024
Primary immunodeficiency, PLI, Tax, EBT, Growth, Biologics license application, Dreieich, Partnership, Patient, Research, Grifols, Management, Technology transfer, Disclosure, PID, Annual report, Next Level, S.A, Birth, FDA, BLA, Fibrinogen, Factor

In the financial year 2023, the Biotest Group generated revenue of € 684.6 million compared with € 516.1 million in the previous year.

Key Points: 
  • In the financial year 2023, the Biotest Group generated revenue of € 684.6 million compared with € 516.1 million in the previous year.
  • The consolidated EBIT result in the 2023 financial year of € 143.5 million improved considerably compared with € -16.6 million in the previous year.
  • In September 2023, Biotest reached an important milestone in the marketing authorisation process for Yimmugo® in the USA.
  • The 2023 Annual Report and the 2023 Sustainability Report are available on the company's website.

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

Retrieved on: 
Monday, March 11, 2024
Health, Pharmaceutical, Research, CFO, Patient, HAE, Health care, CBO, NDA, American Academy, KALV, Factor, MHRA, Clinical trial, Hereditary angioedema, Safety, Pharmacology, AAAAI, Fiscal year, Food, Pharmaceutical industry

(NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024.

Key Points: 
  • (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the third fiscal quarter ended January 31, 2024.
  • Third Fiscal Quarter Financial Results:
    Revenue: No revenue was recognized for the three months ended January 31, 2024, or January 31, 2023.
  • The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT and KONFIDENT-S trials.
  • The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.

Grifols announces positive topline phase 3 fibrinogen clinical trial results

Retrieved on: 
Wednesday, February 14, 2024
Acquisition, Liver, Bleeding, MCE, USD, SCAP, Immunoglobulin M, FC, Fibrinogen, Wound healing, Standard of care, Fibrin, Risk, Safety, Immunoglobulin G, Element, GRFS, Medicine, Patient, Immunoglobulin A, AFD, Clinical trial, Protein, GRF, Plasma, Factor, CAP, Community-acquired pneumonia, Pharmaceutical industry

AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.

Key Points: 
  • AFD, which typically occurs during surgical procedures when there’s insufficient fibrinogen to arrest bleeding, is commonly treated with cryoprecipitate (a plasma extract) or fresh frozen plasma, both containing fibrinogen.
  • Fibrinogen, a plasma protein produced in the liver, plays a key role in stopping blood loss and in wound healing.
  • “The positive results for Biotest’s fibrinogen are an important milestone and strengthen a Grifols innovation strategy that’s diversified across plasma and non-plasma, balanced between internal and external investments, and includes both shorter- and longer-term development cycles,” said Victor Grifols Deu, Grifols Chief Operating Officer.
  • The acquisition of Biotest has significantly reinforced Grifols’ access to plasma, as well as the company’s pipeline and sales presence.

EQS-News: Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate

Retrieved on: 
Wednesday, February 14, 2024
Birth, Bleeding, Spine, USD, Marketing, Fibrinogen, Standard of care, Adjustment, Safety, Element, AG, Patient, Protein, Clinical trial, Plasma, Factor, Pharmaceutical industry

Biotest announced today that the AdFIrst (Adjusted FIbrinogen replacement strategy) phase III trial met its primary endpoint, demonstrating that Fibrinogen concentrate is non-inferior to standard of care in reducing intraoperative blood loss in patients with acquired fibrinogen deficiency undergoing planned major spinal or abdominal surgery.

Key Points: 
  • Biotest announced today that the AdFIrst (Adjusted FIbrinogen replacement strategy) phase III trial met its primary endpoint, demonstrating that Fibrinogen concentrate is non-inferior to standard of care in reducing intraoperative blood loss in patients with acquired fibrinogen deficiency undergoing planned major spinal or abdominal surgery.
  • The AdFIrst trial was a prospective, randomised, active-controlled, multicentre phase III trial involving 222 patients undergoing elective spine or abdominal surgery.
  • This would be the first fibrinogen concentrate approved for an acquired fibrinogen deficiency indication in the US.
  • Compared with congenital fibrinogen deficiency, where efficacy has been demonstrated in an earlier trial, the market size for the treatment of acquired fibrinogen deficiency is many times larger.

Q4 Inc. Reports Continued Progress in Third Quarter 2023 Results

Retrieved on: 
Monday, November 13, 2023
Professional Services, Communications, Technology, Mobile, Wireless, Finance, Internet, Public Relations, Investor Relations, SEDAR, G&A, Bank statement, Marketing, Growth, Perception, Factor, Research, Tax

Our key performance indicators may be calculated in a manner different from similar key performance indicators used by other companies.

Key Points: 
  • Our key performance indicators may be calculated in a manner different from similar key performance indicators used by other companies.
  • Definitions of these key performance indicators can be found under the heading “Key Performance Indicators” in the Company’s management’s discussion and analysis for the three months ended September 30, 2023 and 2022.
  • This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws.
  • Additional information relating to Q4, can be found on SEDAR under the Company’s profile at www.sedar.com .

Kinetex Secures Funding to Build Future of Cross-Chain Trading On Gnosis Chain

Retrieved on: 
Wednesday, November 15, 2023
Gnosis, Ethereum, TVL, Factor, Prejudice, EVM, Lead, Partnership, Flash, Decentralized finance, ZK, Certification path validation algorithm, Cryptocurrency, Telegraphy, Bridge

GIBRALTAR, Nov. 15, 2023 /PRNewswire/ -- Kinetex, a trailblazing decentralized platform that enables highly efficient cross-chain trading, announced the successful close of its strategic funding round. Taking the lead are Factor and Gnosis Chain, a community-led EVM Layer-1 blockchain. This partnership empowers Kinetex to refine its groundbreaking trading approach to transferring liquidity between networks that eliminates the need to store assets in pools and leverages zero-knowledge (ZK) technology to achieve validation without relying on third parties.

Key Points: 
  • Kinetex's Strategic Funding Round is led by Factor and Gnosis Chain, a community-owned EVM (Ethereum Virtual Machine) Layer-1 blockchain prioritizing credible neutrality.
  • GIBRALTAR, Nov. 15, 2023 /PRNewswire/ -- Kinetex , a trailblazing decentralized platform that enables highly efficient cross-chain trading, announced the successful close of its strategic funding round.
  • "With the support of Gnosis Chain and Factor, Kinetex is poised to redefine DeFi," says Tigran Bolshoi, Co-Founder of Kinetex.
  • Kinetex is in the final stages of testing the Flash Trade mode, before launching on Gnosis Chain by the end of the year.

Kinetex Secures Funding to Build Future of Cross-Chain Trading On Gnosis Chain

Retrieved on: 
Wednesday, November 15, 2023
Gnosis, Ethereum, TVL, Factor, Prejudice, EVM, Lead, Partnership, Flash, Decentralized finance, ZK, Certification path validation algorithm, Cryptocurrency, Telegraphy, Bridge

GIBRALTAR, Nov. 15, 2023 /PRNewswire/ -- Kinetex, a trailblazing decentralized platform that enables highly efficient cross-chain trading, announced the successful close of its strategic funding round. Taking the lead are Factor and Gnosis Chain, a community-led EVM Layer-1 blockchain. This partnership empowers Kinetex to refine its groundbreaking trading approach to transferring liquidity between networks that eliminates the need to store assets in pools and leverages zero-knowledge (ZK) technology to achieve validation without relying on third parties.

Key Points: 
  • Kinetex's Strategic Funding Round is led by Factor and Gnosis Chain, a community-owned EVM (Ethereum Virtual Machine) Layer-1 blockchain prioritizing credible neutrality.
  • GIBRALTAR, Nov. 15, 2023 /PRNewswire/ -- Kinetex , a trailblazing decentralized platform that enables highly efficient cross-chain trading, announced the successful close of its strategic funding round.
  • "With the support of Gnosis Chain and Factor, Kinetex is poised to redefine DeFi," says Tigran Bolshoi, Co-Founder of Kinetex.
  • Kinetex is in the final stages of testing the Flash Trade mode, before launching on Gnosis Chain by the end of the year.

EQS-News: Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023

Retrieved on: 
Tuesday, November 7, 2023
Knowledge, FDA, Board of Management St. Molaga's National School v The Secretary General of the Department of Education and Science, Plasma, Technology transfer, Tax, III, Biologics license application, SCAP, US Foods, Factor, Research, EBIT, PID, Phase, Fibrinogen, Marketing, ITP, S.A, Management, Patient, BLA, Bank, Pharmaceutical industry

This development is due to the higher income taxes in connection with the earnings effect from technology disclosure and development services.

Key Points: 
  • This development is due to the higher income taxes in connection with the earnings effect from technology disclosure and development services.
  • This is equivalent to earnings per ordinary share of € 2.22 compared with € - 0.87 in the same period of the previous year.
  • In September 2023, Biotest also reached an important milestone in the marketing authorisation process for Yimmugo in the USA.
  • This revenue growth is enabled by the commissioning of the Yimmugo® production facility within Biotest Next Level.

Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace

Retrieved on: 
Wednesday, November 1, 2023
Data Management, Practice Management, Technology, Managed Care, Other Health, Health, Health Technology, Software, Hospitals, Networks, Mobile, Wireless, XIII, CERS, Von Willebrand factor, Cerus Corporation, Factor XIII, Organization, Factor, Hemostasis, Multimedia, Hospital, Blood, Bleeding, Friction, Patient, China Biologic Products, Pharmaceutical industry

Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace.

Key Points: 
  • Bloodbuy, a healthcare software and services company focused on developing cloud-based technologies that transform how biological products are managed and disseminated, today announced that it has entered into an agreement with Cerus Corporation (NASDAQ: CERS) to offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT® Fibrinogen Complex, or “IFC”) via the Bloodbuy online marketplace.
  • Bloodbuy’s flagship cloud-based platform connects hospitals, blood centers, and life sciences organizations using its multi-patented B2B e-commerce and computer networking technologies for blood and biological products.
  • View the full release here: https://www.businesswire.com/news/home/20231101749546/en/
    Bloodbuy Announces Agreement with Cerus Corporation to Offer Pathogen Reduced Cryoprecipitated Fibrinogen Complex on its Digital Marketplace (Photo: Business Wire)
    IFC is a pathogen reduced blood component for fibrinogen supplementation with a 5-day post-thaw shelf life.
  • Bloodbuy enables blood centers and hospitals, via its unique online marketplace, to redistribute available blood products quickly and easily across its vast network, taking the friction out of this mission critical activity.

Factor Capital Management Launches - Targets 30M Venture Fund I to Invest in Blockchain Technology Startups

Retrieved on: 
Thursday, November 2, 2023
Theta, Cosmos, Blockchain, Life, Investment, Factor, AI, Capital, Sigma Investments Group, Cryptocurrency, Neutral

The fund aims to invest up to $30m in seed-stage startups that leverage blockchain technology to solve real-world problems.

Key Points: 
  • The fund aims to invest up to $30m in seed-stage startups that leverage blockchain technology to solve real-world problems.
  • Venture Fund I is backed by a group of investors, including GSR Markets , Theta Capital Management , executives from Two Sigma Investments, and the founders of Multicoin Capital, Lattice Capital, and Cosmos Network, amongst others.
  • Blockchain technology has promised to change the way we conduct business by introducing trustless efficiencies in archaic analog systems.
  • While the early applications of blockchain technology were often associated with cryptocurrencies and speculation, the technology has come a long way since its inception.